Krystal Biotech Quarterly Balance Sheet
NASDAQ: KRYSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Krystal Biotech financial position
As of Jun 30, 2026, Krystal Biotech reported total assets of $1.50 billion, up 31.8% from a year earlier against total liabilities of $141.5 million. Shareholders' equity stood at $1.36 billion, or 90.6% of assets. The company held $427.7 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 8.32, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Krystal Biotech balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 427.74M | 501.31M | 496.30M | 392.60M | 353.83M | 308.77M | 344.87M | 373.97M | 345.79M | 359.01M | 358.33M | 373.24M |
| Short-Term Investments | 417.89M | 322.09M | 331.49M | 338.46M | 328.16M | 308.08M | 252.65M | 214.36M | 213.83M | 179.25M | 173.85M | 188.83M |
| Receivables | 138.66M | 127.02M | 127.42M | 129.63M | 111.44M | 103.26M | 104.75M | 97.30M | 103.24M | 104.75M | 42.04M | 9.32M |
| Inventory | 45.56M | 42.65M | 40.48M | 37.63M | 31.04M | 29.94M | 26.51M | 18.58M | 12.18M | 11.04M | 6.99M | 5.28M |
| Total Current Assets | 1.06B | 1.02B | 1.02B | 925.65M | 841.35M | 766.80M | 742.04M | 713.16M | 682.77M | 602.25M | 587.91M | 582.13M |
| Property, Plant & Equipment | 153.78M | 153.58M | 150.78M | 148.87M | 150.39M | 151.07M | 155.17M | 156.59M | 158.81M | 160.01M | 161.20M | 164.03M |
| Long-Term Investments | 257.29M | 193.49M | 128.07M | 133.11M | 138.81M | 148.47M | 152.11M | 105.89M | 69.29M | 84.00M | 61.95M | 36.55M |
| Total Assets | 1.50B | 1.40B | 1.33B | 1.24B | 1.14B | 1.07B | 1.06B | 982.32M | 917.66M | 853.30M | 818.36M | 790.35M |
| Accounts Payable | 6.54M | 4.09M | 3.24M | 2.10M | 7.12M | 2.67M | 4.99M | 5.58M | 5.42M | 5.36M | 4.13M | 4.34M |
| Total Current Liabilities | 127.40M | 107.80M | 102.94M | 91.27M | 86.90M | 79.49M | 102.00M | 89.53M | 71.85M | 47.59M | 33.09M | 27.58M |
| Total Liabilities | 141.52M | 120.24M | 114.23M | 102.22M | 97.75M | 89.74M | 109.46M | 96.47M | 78.77M | 54.05M | 39.71M | 34.40M |
| Shareholders' Equity | 1.36B | 1.28B | 1.22B | 1.14B | 1.04B | 984.67M | 946.38M | 885.85M | 838.89M | 799.24M | 778.64M | 755.95M |
| Retained Earnings | 134.86M | 80.09M | 24.16M | -27.24M | -106.60M | -144.94M | -180.67M | -226.15M | -253.33M | -268.89M | -269.83M | -278.52M |
| Net Cash (Debt) | 845.63M | 823.40M | 827.79M | 731.07M | 681.99M | 616.85M | 597.52M | 588.32M | 559.61M | 538.26M | 532.18M | 562.07M |
| Shares Outstanding | 29.60M | 29.44M | 29.19M | 28.98M | 28.93M | 28.90M | 28.79M | 28.76M | 28.71M | 28.53M | 28.24M | 28.19M |
This table shows 12 quarterly periods of Krystal Biotech's balance sheet, from Q2 2026 back to Q3 2023, across 15 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow KRYS's reporting calendar. What is a balance sheet?